Randomized Phase 2 Study of Tivantinib plus Erlotinib versus Single-agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-small Cell Lung Cancer

BACKGROUND: KRAS mutations are identified in approximately 25% of non-small cell lung cancer (NSCLC) cases and are associated with resistance to currently available targeted therapies. The MET oncogene may be implicated in malignant progression of KRAS-mutant tumors. In a pre-specified subset analys...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lung Cancer
Hlavní autoři: Gerber, David E., Socinski, Mark A., Neal, Joel W., Wakelee, Heather A., Shirai, Keisuke, Sequist, Lecia V., Rosovsky, Rachel P., Lilenbaum, Rogerio C., Bastos, Bruno R., Huang, Chao, Johnson, Melissa L., Hesketh, Paul J., Subramaniam, Deepa S., Dietrich, Martin F., Chai, Feng, Wang, Yunxia, Kazakin, Julia, Schwartz, Brian, Schiller, Joan H., Brahmer, Julie R., Kelly, Ronan J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836800/
https://ncbi.nlm.nih.gov/pubmed/29496255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2018.01.010
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky